Your session is about to expire
← Back to Search
TIL Therapy for Cervical Cancer
Study Summary
This trial is testing a new cancer treatment that uses a patient's own immune cells to fight their cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am receiving a specific chemotherapy regimen before my transplant.You have a condition that weakens your immune system, like severe combined immunodeficiency (SCID) or acquired immunodeficiency syndrome (AIDS).My heart's pumping ability is below normal, or I have moderate to severe heart problems.I have received bevacizumab and chemotherapy together before.I don't have severe side effects from previous treatments, except for nerve issues, hair loss, or skin color changes.I have not had an organ transplant or cell therapy, except for LN-145.I am under legal protection or unable to give consent myself.I have a tumor that can be surgically removed and is at least 1.5 cm wide.I do not have serious infections, bleeding disorders, or major heart, lung, or immune system illnesses.My previous treatments with chemotherapy or chemoradiation for cancer were not part of my ongoing systemic therapy.I haven't had any other cancers in the last 3 years, except for non-threatening skin or bladder cancer.I am unable to give consent due to an emergency situation.I have had immunotherapy for my condition before.I do not have any autoimmune or inflammatory disorders.I am fully active or can carry out light work.My cervical cancer has worsened after 1-3 chemotherapy treatments.My cervical cancer cannot be cured with surgery or radiation.I have received chemotherapy for recurrent or advanced cervical cancer.I stopped all cancer treatments 28 days before my tumor surgery.I don't have any ongoing infections and I am HIV negative.My cancer has grown after my last treatment, confirmed by scans.You have had a bad reaction or allergy to any part of the study drug LN-145 or other medications being used in the study.I am on hemodialysis for end-stage kidney disease.I have not had significant bleeding in the last 2 weeks.My organs are functioning well.I have been treated with drugs like PD-1 or PD-L1 for my recurring or spreading cancer.I've only had chemoradiation or surgery for my cancer, no other treatments.My brain metastases have been treated and stable for at least 14 days.I am 18 years or older.I need more than 10 mg/day of prednisone or an equivalent steroid.I have not received a live vaccine in the last 28 days.I have brain metastases that are either causing symptoms or have not been treated.
- Group 1: Cohort 1 LN-145 monotherapy
- Group 2: Cohort 5 Retreatment Cohort
- Group 3: Cohort 2 LN-145 monotherapy
- Group 4: Cohort 3 - Combination Arm (TIL + Pembrolizumab) - US Only
- Group 5: Cohort 4 - Non-enrolling Cohort
- All Individual Drugs Already Approved - Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What medical conditions does LN-145 typically address?
"LN-145 is an effective treatment option for malignant neoplasms, microsatellite instability high, and unresectable melanoma."
What potential risks could be associated with administering LN-145 to patients?
"With prior data backing its safety, but limited evidence for efficacy, LN-145 was assigned a score of 2 out of 3."
Is this research effort currently enrolling volunteers?
"Affirmative. The clinicaltrials.gov website attests that this medical experiment, first posted on June 22nd 2017, is presently looking for participants. Approximately 189 people need to be recruited from 19 different sites."
Are there various sites in the city that are conducting this experiment?
"Eligible patients may be recruited to this clinical trial in three major sites, including University of Southern California Los Angeles (California), University of Chicago (Illinois) and University of California San Diego (Florida). Additionally, there are 19 other recruitment centres."
What is the aim of this investigation?
"This clinical trial's primary goal is to gauge the efficacy and adverse events of LN-145 over a 60 month period. Secondary objectives include measuring disease control rate, overall survival, and side effects in patients with recurrent, metastatic or persistent cervical carcinoma as per RECIST v1.1 guidelines."
What is the sample size of this research experiment?
"Iovance Biotherapeutics, Inc. has set a target of 189 participants for this trial; these individuals must meet the defined inclusion criteria in order to be eligible. This clinical study will take place at University of Southern California and University of Chicago, amongst other medical facilities."
Have any preceding investigations explored the use of LN-145?
"LN-145 was initially analyzed in 2010 at the City of Hope. Presently, there are 250 studies that have been completed as well as 961 active trials taking place largely within Los Angeles County."
Share this study with friends
Copy Link
Messenger